Dr Anjali Mahto shares her experience as the UK’s most experienced user of the 1726 nm laser from Cutera.
Acne is the most common skin condition globally, with more than 83% of the UK population suffering with some form of acne during their lifetime. Having suffered ongoing acne since childhood, I know firsthand the emotional and physical toil suffered by the acne patients who now visit my practice for help on solutions to clear their skin.
Exploring new acne treatments
In 2023, I began hearing about a new laser-based acne therapy – the world’s first to be approved for the long-term treatment of mild, moderate and severe acne using a novel 1726 nm wavelength to directly target the sebaceous gland.
The clinical data I had seen presented by well-known US-based dermatologists was impressive, with trials showing an average 79% reduction in inflammatory lesion count two years post final treatment (n=104).2 As someone always looking for cutting-edge treatments to help my patients, I knew AviClear was something I wanted to bring to my practice.



Patient preference for AviClear
I received the device at Self London in February 2024, and saw good early uptake with my patients. Many of them were keen to try a treatment that offered a long-term solution that does not carry systemic side effects and the same level of follow-up as the oral medications I also offer in the clinic.
This is particularly appealing to a younger patient demographic, many of whom are very health-conscious and looking to avoid pharmacological-based medications such as spironolactone or the gold-standard drug isotretinoin. AviClear fits seamlessly into their lifestyles, providing long-lasting results without the need for lengthy recovery or intensive regimens.

My results with AviClear
Having now treated more than 100 patients at the clinic, I have been very pleased with the clinical results I have achieved. Despite AviClear being delivered monotherapy during all clinical trials prior to launch, in practice I will sometimes combine the treatment with low-dose isotretinoin, spironolactone and/or antibiotics to accelerate treatment results and help manage any potential flare.
I am also treating truncal acne, mostly on the back, using AviClear, and I am seeing good results. In addition to an average +2 grade improvement in acne, patients report a noticeable improvement in oiliness, a reduction in pore size and generally better tone, texture and overall skin health after three 30-minute session with AviClear.
The treatment is highly tolerable, with patients experiencing mild to moderate discomfort.


A breakthrough in acne treatment
For me, AviClear is more than just a treatment – it’s a milestone in dermatology and acne treatment. It’s the solution I wish I had had during my own struggles with acne, and it is now offering patients an organic type of treatment approach. As someone who has walked the same path as many of my patients, I know firsthand the profound difference it can make to their lives.
Eleven months into my experience using AviClear, I am even more excited about what the future holds for this new treatment and the potential future approvals and indications to follow using 1726 nm.
Dr Anjali Mahto is one of the UK’s leading consultant dermatologists. She is a Fellow of the Royal College of Physicians, member of the Royal Society of Medicine and a spokesperson for The British Skin Foundation. In 2023 Dr Mahto opened Self London, a dermatology and lifestyle clinic aimed at managing skin conditions holistically.
Qual: FRCP (Derm), MBBCh, BSc
References
- Goldberg D, et al. ‘Treatment of mild to severe acne with 1726 nm laser: A safe alternative to traditional acne therapies’ Journal of Cosmetic Dermatology (2023).
- Scopelliti M, Kothare A, Karavitis M. ‘A novel 1726‑nm laser system for safe and effective treatment of acne vulgaris’ Journal of Cosmetic Dermatologist (2022).